Sunday, 21 July 2024

Business News

JMP Securities Remains a Buy on Altimmune (ALT) – TipRanks Financial Blog

Provention Bio price target raised to $30 from $24 at Chardan

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Altimmune (ALTResearch Report), with a price target of $15.00. The company’s shares closed yesterday at $2.71.

Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Madrigal Pharmaceuticals, and Ocular Therapeutix. According to TipRanks, Wolleben has an average return of 0.4% and a 34.40% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Altimmune with a $17.50 average price target, implying a 545.76% upside from current levels. In a report released on September 13, Piper Sandler also assigned a Buy rating to the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

ALT market cap is currently $153.8M and has a P/E ratio of -1.79.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

Read More on ALT:

Click Here to Read the Full Original Article at TipRanks Financial Blog…